Literature DB >> 10204198

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

T A Gooley1, W Leisenring, J Crowley, B E Storer.   

Abstract

A topic that has received attention in both the statistical and medical literature is the estimation of the probability of failure for endpoints that are subject to competing risks. Despite this, it is not uncommon to see the complement of the Kaplan-Meier estimate used in this setting and interpreted as the probability of failure. If one desires an estimate that can be interpreted in this way, however, the cumulative incidence estimate is the appropriate tool to use in such situations. We believe the more commonly seen representations of the Kaplan-Meier estimate and the cumulative incidence estimate do not lend themselves to easy explanation and understanding of this interpretation. We present, therefore, a representation of each estimate in a manner not ordinarily seen, each representation utilizing the concept of censored observations being 'redistributed to the right.' We feel these allow a more intuitive understanding of each estimate and therefore an appreciation of why the Kaplan-Meier method is inappropriate for estimation purposes in the presence of competing risks, while the cumulative incidence estimate is appropriate.

Mesh:

Year:  1999        PMID: 10204198     DOI: 10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  869 in total

Review 1.  Logistic or Cox model to identify risk factors of nosocomial infection: still a controversial issue.

Authors:  S Chevret
Journal:  Intensive Care Med       Date:  2001-10       Impact factor: 17.440

2.  Long-Term Risk of Skin Cancer Among Childhood Cancer Survivors: A DCOG-LATER Cohort Study.

Authors:  Jop C Teepen; Judith L Kok; Leontien C Kremer; Wim J E Tissing; Marry M van den Heuvel-Eibrink; Jacqueline J Loonen; Dorine Bresters; Helena J van der Pal; Birgitta Versluys; Eline van Dulmen-den Broeder; Tamar Nijsten; Michael Hauptmann; Nynke Hollema; Wil V Dolsma; Flora E van Leeuwen; Cécile M Ronckers
Journal:  J Natl Cancer Inst       Date:  2019-08-01       Impact factor: 13.506

3.  Comparison of outcomes after HLA-matched sibling and unrelated donor transplantation for children with high-risk acute lymphoblastic leukemia.

Authors:  Mei-Jie Zhang; Stella M Davies; Bruce M Camitta; Brent Logan; Karin Tiedemann; Mary Eapen; Elizabeth L Thiel
Journal:  Biol Blood Marrow Transplant       Date:  2012-03-06       Impact factor: 5.742

4.  Application of therapeutic hypothermia in the intensive care unit.

Authors:  John L Moran; Patricia J Solomon
Journal:  Intensive Care Med       Date:  2004-09-14       Impact factor: 17.440

5.  Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis.

Authors:  Daniel Weisdorf; Mary Eapen; Annalisa Ruggeri; Mei-Jie Zhang; Xiaobo Zhong; Claudio Brunstein; Celalettin Ustun; Vanderson Rocha; Eliane Gluckman
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-26       Impact factor: 5.742

6.  Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development.

Authors:  Natalia Nowak; Jan Skupien; Adam M Smiles; Masayuki Yamanouchi; Monika A Niewczas; Andrzej T Galecki; Kevin L Duffin; Matthew D Breyer; Nick Pullen; Joseph V Bonventre; Andrzej S Krolewski
Journal:  Kidney Int       Date:  2018-02-02       Impact factor: 10.612

7.  Control of infectious mortality due to carbapenemase-producing Klebsiella pneumoniae in hematopoietic stem cell transplantation.

Authors:  A Forcina; R Baldan; V Marasco; P Cichero; A Bondanza; M Noviello; S Piemontese; C Soliman; R Greco; F Lorentino; F Giglio; C Messina; M Carrabba; M Bernardi; J Peccatori; M Moro; A Biancardi; P Nizzero; P Scarpellini; D M Cirillo; N Mancini; C Corti; M Clementi; F Ciceri
Journal:  Bone Marrow Transplant       Date:  2016-09-26       Impact factor: 5.483

8.  Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease.

Authors:  Yoshihiro Inamoto; Barry E Storer; Stephanie J Lee; Paul A Carpenter; Brenda M Sandmaier; Mary E D Flowers; Paul J Martin
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

9.  High incidence of chronic graft-versus-host disease after myeloablative allogeneic stem cell transplantation for chronic lymphocytic leukemia in Sweden: graft-versus-leukemia effect protects against relapse.

Authors:  Maciej Machaczka; Jan-Erik Johansson; Mats Remberger; Helene Hallböök; Vladimir Lj Lazarevic; Björn Engelbrekt Wahlin; Hamdy Omar; Anders Wahlin; Gunnar Juliusson; Eva Kimby; Hans Hägglund
Journal:  Med Oncol       Date:  2013-11-09       Impact factor: 3.064

10.  Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens.

Authors:  Menachem Bitan; Wensheng He; Mei-Jie Zhang; Hisham Abdel-Azim; Mouhab Fakhreddine Ayas; Bella Bielorai; Paul A Carpenter; Mitchell S Cairo; Miguel Angel Diaz; John T Horan; Sonata Jodele; Carrie L Kitko; Kirk R Schultz; Morris Kletzel; Kimberly A Kasow; Leslie E Lehmann; Parinda A Mehta; Nirali Shah; Michael A Pulsipher; Tim Prestidge; Adriana Seber; Shalini Shenoy; Ann E Woolfrey; Lolie C Yu; Stella M Davies
Journal:  Blood       Date:  2014-01-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.